Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PSTV | US
-0.04
-2.78%
Healthcare
Biotechnology
30/06/2024
21/10/2024
1.40
1.45
1.45
1.38
Plus Therapeutics Inc. a clinical-stage pharmaceutical company focuses on the development manufacture and commercialization of treatments for patients with cancer and other diseases. Its lead drug candidate is Rhenium-186Re obisbemeda a patented radiotherapy that targets central nervous system cancers including recurrent glioblastoma leptomeningeal metastases and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics Inc. and changed its name to Plus Therapeutics Inc. in July 2019. Plus Therapeutics Inc. was founded in 1996 and is headquartered in Austin Texas.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
72.4%1 month
131.8%3 months
96.8%6 months
91.0%-
-
3.76
-0.45
0.31
-0.30
18.19
-
-13.47M
8.25M
8.25M
-
-289.05
-
-31.00
-522.50
1.20
1.65
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.30
Range1M
0.74
Range3M
0.81
Rel. volume
0.18
Price X volume
19.76K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Arsanis Inc | ASNS | Biotechnology | 1.38 | 8.30M | -4.83% | n/a | 252.35% |
Soligenix Inc | SNGX | Biotechnology | 3.59 | 8.19M | -7.12% | n/a | 84.28% |
TFFP | TFFP | Biotechnology | 2.3 | 7.97M | 11.11% | n/a | 1.26% |
Alzamend Neuro Inc. Common Stock | ALZN | Biotechnology | 1.73 | 7.74M | 3.28% | n/a | 0.00% |
Moleculin Biotech Inc | MBRX | Biotechnology | 2.67 | 7.59M | 3.29% | n/a | 3.00% |
Pulmatrix Inc | PULM | Biotechnology | 2.04 | 7.45M | 0.97% | n/a | 0.18% |
Cyclerion Therapeutics Inc | CYCN | Biotechnology | 2.9099 | 7.32M | 16.40% | n/a | 0.00% |
Orgenesis Inc | ORGS | Biotechnology | 1.53 | 7.30M | -27.49% | n/a | -84.02% |
Virax Biolabs Group Limited Ordinary Shares | VRAX | Biotechnology | 1.63 | 7.08M | 6.54% | n/a | 4.18% |
Purple Biotech Ltd | PPBT | Biotechnology | 4.49 | 7.07M | 2.75% | n/a | 0.89% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5263 | 7.69M | -2.17% | 0.03 | 16.03% |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.4659 | 4.44M | -2.96% | n/a | 19.98% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.19 | 2.99M | -13.68% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.06 | 2.71M | 0.00% | n/a | 17.32% |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 3.65 | 2.01M | -6.89% | n/a | 0.00% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.30 | 0.53 | Cheaper |
Ent. to Revenue | 18.19 | 3,967.00 | Cheaper |
PE Ratio | - | 41.03 | - |
Price to Book | 3.76 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 96.83 | 72.80 | Riskier |
Debt to Equity | -0.45 | -1.23 | Expensive |
Debt to Assets | 0.31 | 0.25 | Expensive |
Market Cap | 8.25M | 3.66B | Emerging |